Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Clinical Trials as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl Peptidase 4 / blood
-
Dipeptidyl-Peptidase IV Inhibitors*
-
Glucagon-Like Peptide 1 / antagonists & inhibitors*
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Insulin Resistance / physiology
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use*
-
Pyrazines / adverse effects
-
Pyrazines / pharmacology
-
Pyrazines / therapeutic use*
-
Sitagliptin Phosphate
-
Triazoles / adverse effects
-
Triazoles / pharmacology
-
Triazoles / therapeutic use*
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Protease Inhibitors
-
Pyrazines
-
Triazoles
-
Glucagon-Like Peptide 1
-
Dipeptidyl Peptidase 4
-
Sitagliptin Phosphate